Tuesday 13 October 2026
Export ALT’s income statement to Excel — free account
Altimmune, Inc.
Altimmune, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $41,000.00, up 105.0% from fiscal 2024. In the quarter to June 2026, revenue grew 520.0%, EPS grew 55.6%, free cash flow fell 25.3% and total debt rose 142.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.46
0.10
−3.91%
Follow ALT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | — | — |
P/S ratio |
16,855.29 | 6,914.26 | — | — | |
P/FCF ratio |
0.00 | 0.00 | — | — | |
P/Operating CF |
(28.34) | (16.35) | — | — | |
P/B ratio |
1.82 | 1.41 | — | — | |
Price to Tangible BV |
1.95 | 1.50 | — | — | |
EV/Sales |
7,045.34 | 1,717.80 | — | — | |
EV/EBITDA |
0.00 | 0.00 | — | — | |
EV/Operating CF |
(2.12) | (1.17) | — | — | |
EV/FCF |
(2.12) | (1.17) | — | — | |
Quick Ratio |
16.83 | 18.35 | 29.43 | 26.37 | |
Current Ratio |
17.18 | 18.55 | 29.56 | 26.78 | |
Net Debt/EBITDA |
9.39 | 8.09 | 11.94 | 10.82 | |
Debt/Assets |
6.61% | 12.25% | 10.28% | 6.59% | |
Debt/Equity |
0.08 | 0.15 | 0.12 | 0.07 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.63 | 0.71 | 0.93 | 1.06 | |
Capex/Depreciation |
0.00 | 0.00 | 0.03 | 0.04 | |
Interest Coverage |
(42.14) | (32.98) | (22.70) | (23.91) | |
Research and Development Expense of Revenue |
299,200.00% | 59,383.87% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
118,080.00% | 33,903.23% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
71,080.00% | 15,938.71% | 0.00% | 0.00% | |
Graham Net Nets |
0.55 | 0.70 | — | — | |
Graham Number |
0.00 | 0.00 | — | — | |
Earnings Yield |
(28.38%) | (27.98%) | — | — | |
Free Cash Flow Yield |
(19.74%) | (21.30%) | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.13) | (0.22) | (0.17) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.13) | (0.22) | (0.17) | (0.13) | |
Cash per Share |
2.36 | 3.10 | 2.66 | 1.76 | |
Shareholders Equity per Share |
2.08 | 2.55 | 2.28 | 2.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.08 | 2.55 | 2.28 | 2.56 | |
Free Cash Flow |
(11.90) | (19.45) | (20.96) | (24.25) | |
Working Capital |
204.01 | 263.20 | 323.35 | 322.31 | |
Capital Expenditures |
0.00 | 0.00 | (0.02) | (0.03) | |
Net Current Asset Value |
183.77 | 223.16 | 283.03 | 281.81 | |
EV/EBIT |
0.00 | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
2.37 | 2.43 | 2.06 | 2.11 | |
Average Payables |
2.97 | 1.46 | 1.30 | 1.06 | |
Average Assets |
183.16 | 209.62 | 246.45 | 358.78 | |
Average Common Equity |
159.49 | 174.20 | 213.07 | 317.79 |
Columns are period end dates